TOI compared with STLN: revenue, margins and what each company keeps, and the suppliers and customers both name

TOIOncology Institute, Inc.

Mkt capRevenueRevenue

STLNStarling Oncology, Inc.

Mkt capRevenueRevenue

Compare

TOIOncology Institute, Inc.

STLNStarling Oncology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TOI

1 of 3at or beyond implied

Reportimpliedrealized× implied

Nov 6 '26—▼−45.97%—

Q2 FY26±13.5%▲+28.46%×2.11

May 8 '26±18.3%▼−1.72%×0.09

Q1 FY26±75.8%▲+8.40%×0.11

STLN1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Nov 6 '26±32.7%▼−45.97%×1.41

= impliedTOI realized, solidSTLN realized, hatchedOne scale, both sides: full bar = 76%× = |realized| ÷ impliedSource: market data

TOIOncology Institute, Inc.

3.59▼−46.36%· post 3.62

Mkt cap$369.2MRevenue$170MQ3 FY26Revenue$503MFY25

STLNStarling Oncology, Inc.

3.59▼−46.36%· post 3.62

ClosedNov 6 '26

Mkt cap$369.2MRevenue$170MQ3 FY26Revenue$503MFY25

Compare

ClosedNov 6 '26

TOIOncology Institute, Inc.

STLNStarling Oncology, Inc.

3.59▼−46.36%post 3.62

Price

3.59▼−46.36%post 3.62

$369.2M

Mkt cap

$369.2M

Q3 FY26$170M

Revenue

$170MQ3 FY26

FY25$503M

Revenue

$503MFY25

TOI3.59▼−46.36%vsSTLN3.59▼−46.36%ClosedNov 6 '26